This is a REALLY interesting article to me – we are a little undecided about Marshall’s infection type.
“SAN FRANCISCO, CA — October 11, 2005 — Clinical presentation and outcomes for patients with community-acquired methicillin-resistant Staphylococcus aureus (CAMRSA) are significantly different from those of patients who acquire the bacterium in hospital (HAMRSA).Researchers presented these findings here on October 8th at the annual meeting of the Infectious Disease Society of America (IDSA).”
News – Invasive Community-Acquired MRSA Differs from Hospital-Acquired Infections: Presented at IDSA
2 responses so far ↓
Dr Umesh Kumar // Jan 25, 2007 at 11:42 pm
Hai,
I am interested in epidemiology and microbiology of CAMRSA which has emerged and will pose a lot of problems in future.
I would like to know if there are reports from UK of PVL -ve CAMRSA.
Also other intersting articles and updates on CAMRSA.
Wonderful to host a seperate site for this
Bruce Smeaton // May 9, 2011 at 7:02 pm
@Dr Umesh Kumar: Given your interest in CAMRSA I would invite you to go to the American Journal Of Infection Control (online if you don’t currently subscribe) and look at the “Articles In Press” in the current (May 2011) edition…and you will see the first one listed is a peer reviewed study entitled: Effectiveness of a Novel Ozone-Based System for the Rapid High-Level Disinfection of Healthcare Spaces and Surfaces”.
The journal article itself refers to an emerging infection control technology known as AsepticSure.
While the testing and clinical studies published in the article relate to “confined space” scenarios, the developer of AsepticSure is at an advanced stage in designing applications to deal with CAMRSA “hotspots” such as: school locker rooms, gymnasiums, hotels, cruise ships etc.
Dr Michael Shannon (former Canadian Deputy Surgeon General) and Dr Dick Zoutman are just two of the string of eminent professionals working on this technology.
On the science side, you’ll be very intrigued to note that for the first time ever, 100% microbial kill rates measured as minimal reductions rates ranging from 6 – 7.9 log are being consistently achieved against spores including: MRSA, VRE, E.coli, P. aeruginosa, C.difficile and B.subtilis.
100% kill rates at these logs are unprecedented and open up the very real possibility of attacking CAMRSA as well.
If this is of interest to you, you could also do some good due diligence on the science behind the Asepticsure development by checking out the website of Medizone International.
Dr Zoutman is presenting AsepticSure to the World Health Organization-sponsored “First International Conference On Prevention & Infection Control” in Geneva at the end of June. So clearly, this is a development in the fight against superbugs and HAI’s that warrants more than just a cursory glance.
Hope that helps you
Leave a Comment